Immune Profiling After Allogeneic Hematopoietic Cell Transplantation in Pediatric Acute Myeloid Leukemia
Overview
Authors
Affiliations
Although allogeneic hematopoietic cell transplant (allo-HCT) is curative for high-risk pediatric acute myeloid leukemia (AML), disease relapse remains the primary cause of posttransplant mortality. To identify pressures imposed by allo-HCT on AML cells that escape the graft-versus-leukemia effect, we evaluated immune signatures at diagnosis and posttransplant relapse in bone marrow samples from 4 pediatric patients using a multimodal single-cell proteogenomic approach. Downregulation of major histocompatibility complex class II expression was most profound in progenitor-like blasts and accompanied by correlative changes in transcriptional regulation. Dysfunction of activated natural killer cells and CD8+ T-cell subsets at relapse was evidenced by the loss of response to interferon gamma, tumor necrosis factor α signaling via NF-κB, and interleukin-2/STAT5 signaling. Clonotype analysis of posttransplant relapse samples revealed an expansion of dysfunctional T cells and enrichment of T-regulatory and T-helper cells. Using novel computational methods, our results illustrate a diverse immune-related transcriptional signature in posttransplant relapses not previously reported in pediatric AML.
Single-cell genomics-based immune and disease monitoring in blood malignancies.
Rathgeber A, Ludwig L, Penter L Clin Hematol Int. 2024; 6(2):62-84.
PMID: 38884110 PMC: 11180218. DOI: 10.46989/001c.117961.
The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy.
Maurer K, Antin J Front Immunol. 2024; 15:1328858.
PMID: 38558819 PMC: 10978651. DOI: 10.3389/fimmu.2024.1328858.
GPR56 in GVL: marker or mechanism?.
Iness A, Bachireddy P Blood. 2024; 143(13):1206-1207.
PMID: 38546637 PMC: 10997899. DOI: 10.1182/blood.2023023448.